The RAS Initiative
More than 30 percent of all human cancers – including 95 percent of pancreatic cancers and 45 percent of colorectal cancers — are driven by mutations of the RAS family of genes. NCI established the RAS initiative in 2013 to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers.
RAS Research Teams
Learn about the nine highly collaborative research teams that compose the RAS Initiative. View their progress, projects, tools, collaborators, and team members.
RAS Community Outreach
Through community and technical collaborations, workshops, and symposia, the RAS Initiative seeks to increase the sharing of knowledge and resources that are essential to defeat cancers caused by mutant RAS genes.
To help solve the 30-year challenge of how to treat RAS-driven cancers, we need an open model of collaboration. Whether you are a dedicated RAS expert or curious researcher, we encourage you to help advance the research by joining our RAS community.
KRASG12C inhibition drives anti-tumour immunity in lung cancer but combinations with anti-PD1 immunotherapy may only benefit patients with ‘inflamed’ tumours
Using a novel immunogenic mouse model of KRAS-mutant lung cancer, the Downward lab asks the questions ‘what is the effect of KRAS G12C on the tumour microenvironment and on anti-tumour immunity?’ and ‘how well will anti-PD1 immunotherapy work in combination with KRAS G12C inhibitors?’